Literature DB >> 20568015

Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.

Arzu Ergen1, Selim İsbir, Özlem Timirci, Atike Tekeli, Turgay İsbir.   

Abstract

Myeloperoxidase is a lysosomal enzyme of polymorphonuclear leucocytes that contributes to inflammatory responses. In previous studies it was shown that MPO was synthesized in atherosclerotic lesions responsible of lipoprotein oxidations. We aimed to determine the MPO -463 G/A gene polymorphism distribution in Turkish population and evaluate the effects of it on myeloperoxidase levels. There were 100 myocardial infarct patients and 100 healthy control subjects in our study. MPO polymorphism was studied by using PCR-RFLP technique and MPO levels were measured by ELISA. It was shown that MPO levels were increasing in patients after myocardial infarct event but there were no effect of MPO -463 G/A polymorphism on MPO levels. It was also found that serum total cholesterol and LDL-cholesterol levels and smoking was contributing factors in increments of MPO enzymes. We observed that MPO levels were increased in CAD but there were no effect of MPO -463 G/A polymorphism on MPO levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20568015     DOI: 10.1007/s11033-010-0181-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

1.  Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease.

Authors:  Folkert W Asselbergs; Wanda F Reynolds; Jan W Cohen-Tervaert; Gillian A J Jessurun; René A Tio
Journal:  Am J Med       Date:  2004-03-15       Impact factor: 4.965

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma.

Authors:  Renliang Zhang; Zhongzhou Shen; William M Nauseef; Stanley L Hazen
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

4.  Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum.

Authors:  D Schmitt; Z Shen; R Zhang; S M Colles; W Wu; R G Salomon; Y Chen; G M Chisolm; S L Hazen
Journal:  Biochemistry       Date:  1999-12-21       Impact factor: 3.162

5.  A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.

Authors:  Eugene A Podrez; Eugenia Poliakov; Zhongzhou Shen; Renliang Zhang; Yijun Deng; Mingjiang Sun; Paula J Finton; Lian Shan; Maria Febbraio; David P Hajjar; Roy L Silverstein; Henry F Hoff; Robert G Salomon; Stanley L Hazen
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

6.  The common variant in the GSTM1 and GSTT1 genes is related to markers of oxidative stress and inflammation in patients with coronary artery disease: a case-only study.

Authors:  Jian-Jin Tang; Ming-Wei Wang; En-zhi Jia; Jian-Jun Yan; Qi-Ming Wang; Jun Zhu; Zhi-Jian Yang; Xiang Lu; Lian-sheng Wang
Journal:  Mol Biol Rep       Date:  2010-01       Impact factor: 2.316

7.  The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs.

Authors:  F Shabani; J McNeil; L Tippett
Journal:  Free Radic Res       Date:  1998-02

8.  Myeloperoxidase, a leukocyte-derived vascular NO oxidase.

Authors:  Jason P Eiserich; Stephan Baldus; Marie-Luise Brennan; Wenxin Ma; Chunxiang Zhang; Albert Tousson; Laura Castro; Aldons J Lusis; William M Nauseef; C Roger White; Bruce A Freeman
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

9.  Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes.

Authors:  G Ndrepepa; S Braun; J Mehilli; N von Beckerath; A Schömig; A Kastrati
Journal:  Eur J Clin Invest       Date:  2008-02       Impact factor: 4.686

Review 10.  Myeloperoxidase and its contributory role in inflammatory vascular disease.

Authors:  Denise Lau; Stephan Baldus
Journal:  Pharmacol Ther       Date:  2006-02-13       Impact factor: 12.310

View more
  4 in total

1.  Effects of MPO-463G/A and -129G/A polymorphisms on coronary artery disease risk and patient survival in a Turkish population.

Authors:  Serdal Arslan; Öcal Berkan; Burcu Bayyurt; Osman Beton; Ni L Özbi Lüm Şahin; Eylem Itır Aydemir
Journal:  Biomed Rep       Date:  2017-10-03

2.  Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortia.

Authors:  Alexander P Reiner; Jaana Hartiala; Tanja Zeller; Joshua C Bis; Josée Dupuis; Myriam Fornage; Jens Baumert; Marcus E Kleber; Philipp S Wild; Stephan Baldus; Suzette J Bielinski; João D Fontes; Thomas Illig; Brendan J Keating; Leslie A Lange; Francisco Ojeda; Martina Müller-Nurasyid; Thomas F Munzel; Bruce M Psaty; Kenneth Rice; Jerome I Rotter; Renate B Schnabel; W H Wilson Tang; Barbara Thorand; Jeanette Erdmann; David R Jacobs; James G Wilson; Wolfgang Koenig; Russell P Tracy; Stefan Blankenberg; Winfried März; Myron D Gross; Emelia J Benjamin; Stanley L Hazen; Hooman Allayee
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

3.  Myeloperoxidase polymorphism and coronary artery disease risk: A meta-analysis.

Authors:  Yan Wang; Xu-Yan Chen; Ke Wang; Shan Li; Xiang-Yang Zhang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

4.  PRISMA-combined Myeloperoxidase -463G/A gene polymorphism and coronary artery disease: A meta-analysis of 4744 subjects.

Authors:  Yan-Yan Li; Hui Wang; Jin Qian; Hyun Jun Kim; Jing-Jing Wu; Lian-Sheng Wang; Chuan-Wei Zhou; Zhi-Jian Yang; Xin-Zheng Lu
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.